Where the pathway breaks — and how we close it
37 percent drop off pre-listing — the funnel collapses early
USRDS 2024 reports approximately 37 percent of patients evaluated for kidney transplant drop off before listing. The bottleneck is no longer organ supply — it is the evaluation pathway itself: psychosocial holds, social-support narratives, transportation friction, missed labs, missed clinic appointments. A waitlist that loses a third of its candidates is a workflow problem dressed up as a clinical one.
Cost when unaddressed: Wolfe 1999 NEJM established the survival case: long-term mortality is 48 to 82 percent lower among transplant recipients than waitlisted dialysis patients. Every month a candidate spends stalled in evaluation is a measurable mortality cost, not a paperwork delay.
Structured navigation across the funnel
Referral → evaluation → listing → post-transplant tracked as a single workflow with SLA-anchored steps. Transportation, lab gaps, no-show recovery, social-support narrative, and SIPAT subscale flags each route to a navigator queue with a clinical owner. Drop-off becomes a tracked failure mode, not an aggregate quarterly statistic.
Caregiver burden is invisible to the clinical record
The transplant candidate's social-support narrative is one paragraph in a chart. The caregiver who is the actual support is never measured. The Zarit Burden Interview — the most-cited caregiver-burden instrument worldwide since 1980 — is rarely administered in transplant programs despite decades of cross-population validation including ESRD/dialysis. Caregiver collapse is the social-support failure mode that ends listings.
Cost when unaddressed: Ladin 2017 explicitly identifies social-support narratives as a primary equity bottleneck in transplant listing — programs apply the standard inconsistently, in ways that disadvantage patients with non-traditional support structures and racial-minority patients in particular.
Zarit + caregiver workflow
Zarit Burden Interview administered at evaluation and at six-month intervals post-listing. Burden subscale flags route to caregiver-support resources, respite coordination, and structured navigator follow-up. Caregiver becomes a measured stakeholder, not a paragraph.
Depression in CKD/ESRD runs ~25 percent — and goes untreated
Palmer 2013 Kidney International meta-analysis (249 populations, 55,982 participants) established interview-defined depression prevalence at 22.8 percent in dialysis (CI 18.6-27.6) and 25.7 percent in transplant recipients (CI 12.8-44.9). Self-report scales register higher, around 39.3 percent in dialysis. Most transplant programs do not screen with PHQ-9 at intake or follow-up. Hedayati 2010 separately tied untreated CKD depression to faster progression to dialysis and higher hospitalization.
Cost when unaddressed: Untreated depression is associated with faster CKD progression, more hospitalization, and post-transplant adherence collapse. The screening instrument exists. The workflow rarely does.
PHQ-9 + clinical follow-up
PHQ-9 administered at evaluation, listing, and quarterly post-transplant. Score-anchored thresholds route to clinical follow-up — not a referral list. CAST sertraline trial (Hedayati 2017) provides the evidence base for SSRI response in CKD-attributable depression; CBT-for-dialysis (Cukor 2014 RCT) provides the non-pharmacological arm. PHQ-9 is the screen, not the treatment.
SIPAT is the standard — but inconsistently applied
The Stanford Integrated Psychosocial Assessment for Transplantation (Maldonado 2012) is the most-validated standardized psychosocial pre-transplant evaluation instrument. Inter-rater reliability runs Pearson 0.853 even among novice raters. SIPAT scores are highly predictive of psychosocial transplant outcome (P < 0.0001). Despite this, programs apply it inconsistently — many still rely on ad-hoc psychosocial evaluation that produces a binary list/no-list decision rather than a continuous, structured-support workflow.
SIPAT as workflow, not gate
SIPAT 4-domain scoring (readiness, social support, psychosocial stability, lifestyle/substance use) administered at evaluation. Subscale flags route to modifiable-risk-factor workflows — not list/no-list bifurcation. Takano 2023 Japan replication confirmed the predictive validity outside the original Stanford cohort. Maldonado 2015 extended validation through 5-year outcome follow-up.
Distance to transplant center is not the problem
McPherson 2020 CJASN cohort (27,250 incident dialysis patients in GA/NC/SC) tested the geographic-distance hypothesis directly: distance from residence to nearest transplant center was NOT significantly associated with referral or evaluation initiation. Only 35 percent were referred within one year. Of those referred, only 58 percent initiated evaluation within six months. The bottleneck is workflow at the dialysis center, not patient geography.
Cost when unaddressed: Distance-targeted policy and outreach grants do not move the metric. The metric is moved by closing the dialysis-center referral workflow gap.
Dialysis-center referral workflow
Dialysis units integrate referral templates, candidate-tracking, and same-program SIPAT pre-screening into the routine encounter — not a separate referral form on a portal nobody opens. Cross-site coordination handles transportation, lab access, and clinic-appointment friction at the workflow level rather than the patient level.
Pediatric adherence collapses post-transplant
Dew 2009 meta-analysis (61 studies) established pediatric solid-organ transplant adherence baselines. Clinic appointment / lab nonadherence runs 12.9 cases per 100 patients per year — the highest-prevalence adherence problem. Immunosuppression nonadherence runs 6 per 100 PPY. Family functioning, parental distress, and child psychological status all correlate with nonadherence. Connelly 2015 confirmed similar nonadherence rates specifically in pediatric kidney transplant follow-up.
Cost when unaddressed: Adherence collapse drives graft rejection. Graft rejection drives readmission and re-listing. The most expensive failure mode in pediatric transplant care is the missed appointment that nobody followed up on within 72 hours.
Adherence workflow + family routing
Appointment-reminder + transportation-coordination workflows directly target the highest-prevalence adherence gap. Family-functioning signals and parental-distress flags from intake screen into navigator queues. PACT (Freischlag 2019) provides a validated pediatric-specific assessment instrument that routes risk factors to pre-transplant intervention rather than post-transplant rescue.
Living donor evaluation has its own attrition curve
The KDIGO 2017 living-donor guideline (Lentine et al.) standardized the evaluation framework, but the workflow of moving a willing donor through medical, psychosocial, and surgical evaluation is its own funnel — and most programs do not measure attrition stage by stage. Richter 2024 validated the Transplant Evaluation Rating Scale (TERS) for living donors, providing a structured psychosocial instrument analogous to SIPAT. Without measurement, willing donors disappear into administrative friction.
Donor-side workflow + TERS
Donor evaluation tracked as a parallel funnel with stage-anchored attrition. TERS administered at psychosocial evaluation. Kumar 2018 documented racial disparities in living-donor kidney transplant access — donor-side workflow surfaces those disparities at the stage at which they fire, instead of letting them disappear into the aggregate.
Methodology
How we measure
Pre-listing drop-off rate is calculated as (candidates who completed evaluation but were never listed) divided by (candidates who initiated evaluation in the measurement period), reported quarterly, anchored against the USRDS 2024 baseline of approximately 37 percent. Referral-to-evaluation conversion is calculated as (candidates who initiated psychosocial + medical evaluation within 6 months of referral) divided by (referrals received), against the McPherson 2020 baseline of 58 percent. SIPAT scores are reported by 4-domain (readiness, social support, psychosocial stability, lifestyle/substance use) per the Maldonado 2012 instrument with the Maldonado 2015 + Takano 2023 validation extensions. KDQOL-36 quality-of-life is administered at evaluation and 6-month intervals per the Chen 2016 Chinese-cohort and Gebrie 2022 Ethiopia-cohort validations. Zarit Burden Interview administered to identified caregivers at the same intervals per the original Zarit 1980 instrument and al-Rawashdeh 2016 cross-population validation. PHQ-9 administered per the Kroenke 2001 validation with the Costantini 2021 meta-analysis sensitivity/specificity benchmarks. Estimated GFR reported per the Levey 2009 CKD-EPI equation.
What counts
- Adult and pediatric kidney transplant candidates from the point of referral through 12 months post-transplant
- Identified caregivers who consent to caregiver-burden assessment
- Living-donor candidates from the point of donor-evaluation initiation through donor surgery follow-up
- Psychosocial assessments completed via SIPAT, KDQOL-36, Zarit Burden Interview, PHQ-9, GAD-7, TERS (donor) within the program's evaluation protocol
- Crisis events handled inside the TransplantCheck workflow with Stanley-Brown safety planning and 24-72 hour clinical follow-up
What doesn't count
- Candidates who relocate out of the program catchment after evaluation initiation but before listing
- Candidates who declined psychosocial assessment despite offered (tracked separately as decline rate, not attrition)
- Self-report scale scores treated as diagnostic — Palmer 2013 documented the interview-vs-scale gap, scales screen, interviews confirm
- Referrals to outside transplant programs where receiving-program confirmation was not obtained within 30 days
- Living-donor evaluations terminated for medical contraindication identified at initial workup (tracked separately as medical-eligibility, not psychosocial-attrition)
How we compare
Sourced from primary citations — not vendor marketing claims.
| Us TransplantCheck | vs Generic patient portal | vs DIY paper SIPAT + spreadsheet | vs Hospital EHR module | |
|---|---|---|---|---|
| Pre-listing drop-off tracking cite | Stage-anchored, attributable to step + owner | None — portal logins are not clinical events | Manual spreadsheet, lossy | Aggregate, not stage-attributable |
| SIPAT workflow cite | 4-domain scored with subscale routing to modifiable-risk-factor queues | Not supported | Paper instrument, ad-hoc scoring | Sometimes available as form, no routing |
| KDQOL-36 quality of life cite | Administered at evaluation + 6-month intervals, validated cohorts | Not supported | Paper instrument, often skipped | Optional form, no longitudinal trend |
| Caregiver Zarit Burden Interview cite | Administered to identified caregivers, subscale-routed | Not supported | Rarely administered | Not supported |
| PHQ-9 + crisis routing cite | Quarterly + Stanley-Brown safety planning + 24-72hr clinical follow-up | Not supported | Inconsistent | Form available, no Stanley-Brown follow-up |
| Living-donor TERS workflow cite | Stage-anchored donor attrition + TERS scoring | Not supported | Not supported | Not supported |
| White-label depth | Total — patient sees program brand, not ours | Generic vendor branding | N/A | EHR vendor branding |
| BAA + HIPAA technical safeguards cite | Executed BAA, 5 safeguards under 45 CFR 164.312 in production | Varies by vendor | Manual — depends on program | Inherits hospital BAA |
| Founder credibility | Built and operated by Matthew Sexton, LCSW — practicing clinician | Vendor sales team | Program social worker — limited bandwidth | EHR vendor — no clinician at the table |
Frequently asked questions
- Why do 37 percent of transplant evaluations end before listing?
- Because pre-evaluation has become the bottleneck, not organ supply. USRDS 2024 reports approximately 37 percent of patients evaluated for kidney transplant drop off before listing. McPherson 2020 CJASN cohort confirmed the bottleneck is workflow at the dialysis center and the evaluation pathway, not patient geography — distance to nearest transplant center was NOT significantly associated with referral or evaluation initiation. The actual drop-off is driven by psychosocial holds, social-support narrative blocks (Ladin 2017 documented the equity disparity here), transportation friction, missed labs, and missed clinic appointments. TransplantCheck rebuilds the funnel as a tracked workflow with SLA-anchored steps and clinical owners, so every drop-off is attributable to a step rather than aggregated into a quarterly statistic.
Cited: usrds-2024-esrd-incidence , mcpherson-2020-distance-transplant-referral , ladin-2017-social-support-transplant
- How does TransplantCheck integrate with our existing transplant team?
- TransplantCheck operates as navigation infrastructure, not a clinical-decision replacement. The transplant nephrologist, surgeon, and program social worker remain the decision-makers. TransplantCheck operationalizes the screening instruments (SIPAT, KDQOL-36, Zarit Burden Interview, PHQ-9) the program already uses (or should be using), routes flagged subscales into navigator queues with clinical owners, and tracks closure-of-loop across referral, evaluation, listing, and post-transplant adherence. White-labeling is total — the patient sees the program's brand, not ours. Maldonado 2012 SIPAT inter-rater reliability runs 0.853 even among novice raters, so the standardized scoring works whether the rater is a senior LCSW or a trainee.
Cited: maldonado-2012-sipat-validation , maldonado-2015-sipat-validation
- What data is shared with the transplant nephrologist and surgeon?
- All clinical assessment data — SIPAT subscales, KDQOL-36 trends, Zarit caregiver burden scores, PHQ-9 trajectories, eGFR per the Levey 2009 CKD-EPI equation, adherence flags, crisis events — is available to the clinical team in the program's existing chart workflow. TransplantCheck does not silo data behind a vendor portal. The five HIPAA technical safeguards under 45 CFR 164.312 — access control, audit controls, integrity controls, person/entity authentication, transmission security — are in production under the program's executed BAA. Patient consent governs what is shared with caregivers, dialysis centers, and outpatient providers, with documented consent flows for each route.
Cited: hhs-45-cfr-164-312-technical-safeguards , levey-2009-ckd-epi-equation
- How are suicidal ideation and crisis events handled?
- Crisis routing is always-on. PHQ-9 item 9 thresholds, GAD-7 acute scores, and SIPAT psychosocial-stability subscale flags trigger Stanley-Brown safety planning embedded in the workflow with 24-72 hour clinical follow-up. The Stanley 2018 ED-cohort study showed safety planning plus structured follow-up reduced subsequent self-harm by roughly 45 percent versus usual care. 988 single-tap and after-hours warm-line lookup are present at every patient touchpoint. Cohen 2016 documented anxiety and ideation prevalence in hemodialysis populations specifically — TransplantCheck treats acute crisis events as a workflow with a clinical owner, not a phone number.
Cited: stanley-2018-safety-planning-ed-cohort , cohen-2016-anxiety-hemodialysis , kroenke-2001-phq9-validation
- How long does deployment take?
- Bespoke quote within 24 hours of the discovery call. Tenant deployment timeline runs program-specific — typical mid-size program lands in 6 to 10 weeks from BAA signature to first patient enrollment, depending on EHR integration depth and white-label asset turnaround. SIPAT, KDQOL-36, Zarit, PHQ-9, GAD-7, and TERS (donor-side) are pre-built — the customization work is around the program's existing referral templates, dialysis-center coordination protocols, and post-transplant adherence cadence. McAdams-DeMarco 2013 frailty + readmission data and Woodside 2021 USRDS AVF procedural-burden data are available as program-comparison benchmarks during the discovery call.
Cited: mcadams-demarco-2013-frailty-transplant-readmission , woodside-2021-avf-procedural-burden-usrds
Why this exists
The bottleneck moved from organ supply to evaluation. TransplantCheck closes the funnel — under your brand.
I built TransplantCheck because the bottleneck moved and most programs are still solving the old problem. Twenty years ago organ supply was the constraint and every workflow optimization went into matching, allocation, and procurement. That war was largely won. The constraint now is the evaluation pathway. Two of three incident dialysis patients are never referred for transplant in the first year. Of the third who are referred, four in ten never start evaluation. By the time you are talking about organ supply, the funnel has already collapsed three times.
The screening instruments exist. SIPAT is twelve years old and the inter-rater reliability runs 0.853 even among novice raters. KDQOL-36 is validated in Chinese, Ethiopian, and U.S. dialysis cohorts. Zarit has been the standard caregiver-burden instrument since 1980. PHQ-9 has been the standard depression screen since 2001. The problem is not the instrument. The problem is the workflow that turns the score into a clinical action with an owner. Most programs run a paper SIPAT, a spreadsheet of candidates, and a social worker with twice the bandwidth she actually has. That is not a system — it is the heroic effort of a single clinician trying to keep a funnel from collapsing.
TransplantCheck is the system underneath that effort. It is white-labeled to the program's brand, operated under the program's BAA, and built by an LCSW who still sees clients. The architecture and the clinician are the same person at the table.
Matthew Sexton, LCSW Founder · Mental Wealth Solutions Inc.
Citations
- (2024). 2024 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
Source
- Incident ESRD cases in 2022 reached approximately 133,000 new patients beginning kidney replacement therapy.
- Prevalent ESRD population on dialysis or with a functioning transplant exceeded 808,000 patients at the end of 2022.
- Kidney transplant waitlist sat near 89,000 candidates with median wait times of 3–5 years for deceased-donor recipients.
“The ESRD population continues to grow, but transplant volume has not kept pace with incidence — the bottleneck is no longer organ supply alone, but evaluation throughput.”
- (1999). Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. New England Journal of Medicine.
doi:10.1056/NEJM199912023412303
- Long-term mortality was 48% to 82% lower among kidney transplant recipients compared with waitlisted dialysis patients.
- Projected gain in life expectancy from transplantation versus continued dialysis was 10 years on average across the analyzed cohort.
- Mortality benefit emerged within 3 to 4 months after transplantation across all demographic subgroups studied.
“Long-term mortality among recipients of a first cadaveric kidney transplant is substantially lower than that of patients who remain on dialysis while waiting for a transplant.”
- (2020). Distance to kidney transplant center and access to early steps in the kidney transplantation process in the southeastern United States. Clinical Journal of the American Society of Nephrology.
doi:10.2215/CJN.08530719
- Greater driving distance from a patient's residence to the nearest transplant center was independently associated with lower odds of being referred for transplant evaluation among incident dialysis patients.
- Geographic disparities in transplant referral persisted after adjusting for demographics, comorbidity, and dialysis-facility characteristics.
- Patients living more than 90 minutes from the nearest transplant center had substantially reduced odds of completing the early steps of the transplant process.
“Distance to kidney transplant center is an independent and modifiable barrier to access to the early steps of the kidney transplantation process, particularly for patients in geographically isolated regions of the southeastern United States.”
- (2012). The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pretransplant candidates. Psychosomatics.
doi:10.1016/j.psym.2011.12.012
- SIPAT incorporates 18 risk items across patient readiness, social support, psychological stability, and lifestyle/effect of substance use.
- Inter-rater reliability among trained raters reached intraclass correlation coefficients above 0.85.
- Higher SIPAT scores at evaluation correlated with worse psychosocial outcomes after transplantation.
“SIPAT provides a standardized psychosocial assessment that minimizes inter-rater variability and operationalizes the previously subjective transplant candidacy decision.”
- (2015). The Stanford Integrated Psychosocial Assessment for Transplantation: a prospective study of medical and psychosocial outcomes. Psychosomatic Medicine.
doi:10.1097/PSY.0000000000000241
- Higher pretransplant SIPAT scores predicted significantly higher rates of medical complications post-transplant.
- Patients with elevated SIPAT scores experienced more rejection episodes, infections, and rehospitalizations.
- Psychosocial measures including depression, support breakdown, and treatment-adherence problems were directly tied to higher SIPAT risk strata.
“Pretransplant SIPAT scores robustly predict post-transplant medical and psychosocial outcomes — making structured psychosocial assessment a clinically actionable risk stratifier.”
- (2023). Validation of the Japanese version of the Stanford Integrated Psychosocial Assessment for Transplantation in liver transplant candidates. Transplantation Proceedings.
doi:10.1016/j.transproceed.2023.04.024
- Cross-cultural validation of the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in a Japanese liver transplant candidate cohort.
- Japanese SIPAT scores showed strong inter-rater reliability and significant association with post-transplant adverse events including nonadherence and rehospitalization.
- Supports international applicability of SIPAT as the global standard for structured pretransplant psychosocial assessment beyond its original North American validation samples.
“The Japanese version of the SIPAT demonstrated acceptable reliability and predictive validity in liver transplant candidates, supporting its use as a structured psychosocial assessment instrument outside North American populations.”
- (1980). Relatives of the impaired elderly: correlates of feelings of burden. The Gerontologist.
doi:10.1093/geront/20.6.649
- Original 29-item Zarit Burden Interview later condensed into the validated 22-item ZBI used worldwide.
- Frequency and severity of patient behavior problems correlated more strongly with caregiver burden than the patient's cognitive impairment severity.
- Founded a measurement framework reused across dementia, oncology, transplant, and chronic kidney disease caregiving research.
“The frequency of memory and behavioral problems in the impaired person was associated with subjective burden, but the relationship was modified by the family situation and the affected relative's response.”
- (2016). The reliability and validity of the Arabic version of the Zarit Burden Interview. Research in Nursing & Health.
doi:10.1002/nur.21737
- Arabic-language Zarit Burden Interview validated in caregivers of patients with heart failure, demonstrating Cronbach alpha exceeding 0.85.
- Convergent validity supported by significant correlations between caregiver burden, depressive symptoms, and perceived stress measures.
- Confirms cross-cultural applicability of the original 22-item ZBI structure across non-Western caregiving contexts and chronic-illness populations beyond dementia.
“The Arabic version of the Zarit Burden Interview is a reliable and valid instrument for measuring caregiver burden in family caregivers of patients with heart failure.”
- (2016). Anxiety in patients treated with hemodialysis. Clinical Journal of the American Society of Nephrology.
doi:10.2215/CJN.02590316
- Anxiety symptom prevalence among hemodialysis patients estimated at 12% to 52% across published cohort studies, with point prevalence consistently exceeding the general population baseline.
- Anxiety in dialysis is independently associated with poorer health-related quality of life, reduced treatment adherence, and increased mortality risk after adjusting for medical comorbidity.
- Pharmacotherapy in dialysis populations is constrained by altered drug clearance and dialyzability of psychotropic medications, making CBT and integrated behavioral interventions first-line options for many patients.
“Anxiety is a common but underdiagnosed and undertreated comorbidity in patients with end-stage renal disease that contributes substantially to morbidity, mortality, and healthcare utilization.”
- (2014). Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis. Journal of the American Society of Nephrology.
doi:10.1681/ASN.2012111134
- Randomized controlled trial of in-center cognitive behavioral therapy delivered in 10 sessions to 65 hemodialysis patients with comorbid depression.
- CBT arm showed significant reductions in Beck Depression Inventory-II scores compared with usual care, sustained at three-month follow-up.
- Interdialytic weight gain — a marker of fluid adherence — improved in the CBT arm relative to control, demonstrating downstream behavioral effects of mental health treatment.
“A chairside cognitive behavioral therapy intervention significantly improved depression, quality of life, and interdialytic weight gain in hemodialysis patients compared with treatment as usual.”
- (2010). Prevalence of major depressive episode in CKD. American Journal of Kidney Diseases.
doi:10.1053/j.ajkd.2009.06.026
- Prevalence of current major depressive episode by structured clinical interview in non-dialysis CKD outpatients was 21%, exceeding general-population estimates by roughly 3 to 4 fold.
- Depressive symptoms by self-report screening instruments such as the BDI overestimated rates of major depression compared with structured clinical interview, highlighting the gap between screening and diagnosis.
- Major depressive episode in CKD was associated with progression to dialysis, hospitalization, and death after multivariable adjustment for kidney function and comorbidity.
“Major depressive disorder is highly prevalent and underrecognized in patients with chronic kidney disease, and its presence independently predicts adverse clinical outcomes.”
- (2017). Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. JAMA.
doi:10.1001/jama.2017.17131
- Multicenter double-blind placebo-controlled randomized trial of sertraline versus placebo for major depressive disorder in 201 non-dialysis CKD patients.
- Sertraline did not show a statistically significant advantage over placebo on the primary outcome of change in Quick Inventory of Depressive Symptomatology score over 12 weeks.
- Trial provides high-quality evidence that pharmacotherapy effects observed in general-population depression trials cannot be assumed to translate to CKD populations.
“Among patients with non-dialysis-dependent chronic kidney disease and major depressive disorder, treatment with sertraline compared with placebo did not result in a significant improvement in depressive symptoms.”
- (2013). Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney International.
doi:10.1038/ki.2013.77
- Pooled prevalence of depression in dialysis patients across 55,982 participants in 249 studies was 22.8% by interview-based diagnosis and 39.3% by symptom-rating scale.
- Pre-dialysis CKD pooled prevalence reached 21.4% by interview and 26.5% by symptom-rating scale, while kidney-transplant recipients showed 25.7% by interview.
- Heterogeneity across studies was high, but every CKD stage and treatment modality showed depression rates substantially above general-population norms.
“Depression is common across all stages of chronic kidney disease, with interview-based prevalence in dialysis patients more than three-fold the rate observed in the general population.”
- (2001). The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine.
doi:10.1046/j.1525-1497.2001.016009606.x
- PHQ-9 score ≥10 had a sensitivity of 88% and a specificity of 88% for major depression in primary-care samples.
- Construct validity demonstrated against the SF-20 functional-status measure across 6,000 primary-care patients in 8 clinics.
- Each 5-point increase on the 0-to-27 PHQ-9 scale corresponded to substantial worsening in functional status, sick-day burden, and healthcare utilization.
“The PHQ-9 is a reliable and valid measure of depression severity. Its brevity and dual purpose for diagnosis and severity assessment make it a useful clinical and research tool.”
- (2021). Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): a systematic review. Journal of Affective Disorders.
doi:10.1016/j.jad.2020.09.131
- Systematic review pooled diagnostic performance data on PHQ-9 from 36 primary-care studies covering more than 28,000 patients across 18 countries.
- PHQ-9 cutoff of 10 yielded a pooled sensitivity in the 80% range and pooled specificity in the 80% to 90% range for major depressive disorder, supporting its use as a primary-care screening instrument.
- Performance was robust across age groups, ethnicities, and primary-care settings, though specificity dropped in populations with high rates of somatic illness due to symptom overlap.
“The PHQ-9 demonstrates acceptable diagnostic accuracy as a screening tool for major depression in adult primary-care populations, with cutoff scores of 10 or above offering an evidence-based threshold for further evaluation.”
- (2009). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine.
doi:10.7326/0003-4819-150-9-200905050-00006
- CKD-EPI equation reduced bias by 65% compared with the legacy MDRD Study equation in the GFR range above 60 mL/min/1.73m².
- Pooled dataset combined 8,254 participants across 10 studies for development and 3,896 participants across 16 studies for validation.
- CKD-EPI lowered estimated CKD prevalence from 13.1% (MDRD) to 11.5% in the U.S. adult NHANES population — reclassifying millions of patients as not having CKD.
“The CKD-EPI equation is more accurate than the MDRD Study equation and could replace it for routine clinical use.”
- (2009). Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation.
doi:10.1097/TP.0b013e3181a440ae
- Meta-analysis pooling 147 studies of post-transplant adherence found average rates of immunosuppressant nonadherence of approximately 23 cases per 100 patients per year across solid-organ recipients.
- Nonadherence rates were substantially higher for clinic-attendance, exercise, and diet domains than for medication-taking, with the latter still showing meaningful prevalence.
- Identified consistent psychosocial risk factors for nonadherence, including poor social support, depression, anxiety, substance use, and demographic vulnerability.
“Nonadherence to the post-transplant regimen is a substantial, multidomain problem with consistent psychosocial risk factors that should inform pretransplant assessment and longitudinal follow-up.”
- (2015). Predictors of nonadherence in pediatric solid organ transplantation. Pediatric Transplantation.
doi:10.1111/petr.12428
- Adolescent transplant recipients show consistently higher rates of immunosuppressant nonadherence than younger pediatric or adult transplant cohorts, contributing to elevated late acute rejection risk.
- Family functioning, parental mental health, and the developmental transition from parent-managed to self-managed regimens were among the strongest psychosocial predictors of post-transplant adherence.
- Structured psychosocial assessment and adolescent-focused transition programs reduced nonadherence-related graft loss in single-center cohort series.
“Adolescence is a high-risk period for nonadherence after pediatric solid organ transplantation, and structured psychosocial assessment combined with transition planning is essential to reducing late graft loss.”
- (2019). Psychosocial assessment of candidates for transplantation (PACT) score identifies high risk patients in pediatric renal transplantation. Frontiers in Pediatrics.
doi:10.3389/fped.2019.00102
- Single-center retrospective study evaluated PACT scores for pediatric kidney-transplant candidates and tracked post-transplant adherence and graft outcomes.
- Lower PACT scores at pretransplant evaluation were significantly associated with post-transplant medication nonadherence and acute rejection episodes.
- Demonstrates utility of structured psychosocial scoring instruments originally developed for adult transplantation in pediatric populations as a complement to clinical interview.
“The PACT score reliably identifies pediatric kidney transplant candidates at elevated risk for post-transplant nonadherence and adverse graft outcomes, supporting its role in structured pretransplant psychosocial assessment.”
- (2013). Frailty and early hospital readmission after kidney transplantation. American Journal of Transplantation.
doi:10.1111/ajt.12300
- Among 383 kidney transplant recipients prospectively assessed using the Fried frailty phenotype, frail recipients had a 61% increased risk of early hospital readmission within 30 days of transplant.
- Frailty was independently predictive of readmission after adjustment for age, comorbidity, and donor type.
- Frailty assessment at the time of transplant identified a vulnerable subgroup that benefitted from intensified post-transplant monitoring and care coordination.
“Frailty, as measured by the Fried frailty phenotype, is an independent predictor of early hospital readmission after kidney transplantation and identifies a high-risk subgroup who may benefit from targeted post-transplant interventions.”
- (2021). Arteriovenous vascular access-related procedural burden among incident hemodialysis patients in the United States. American Journal of Kidney Diseases.
doi:10.1053/j.ajkd.2020.08.016
- Analysis of USRDS data quantified the cumulative procedural burden of arteriovenous fistula and graft creation, maturation, and revision among incident hemodialysis patients.
- Patients required substantially more vascular-access procedures during the first year of dialysis than commonly reported in single-center cohort studies.
- Cumulative procedural burden was associated with increased hospitalization rates and additive psychosocial stress on patients adjusting to ESRD treatment.
“The procedural burden of establishing and maintaining functional arteriovenous vascular access among incident hemodialysis patients in the United States is substantial and contributes to the cumulative psychosocial and clinical burden of ESRD care.”
- (2016). Cross-cultural adaptation and validation of the Chinese version of the Kidney Disease Quality of Life-36 (KDQOL-36). Health and Quality of Life Outcomes.
doi:10.1186/s12955-016-0539-y
- Cross-cultural adaptation and validation of the KDQOL-36 in a Mandarin-speaking population of dialysis patients in Taiwan.
- Internal consistency reliability across the burden, symptoms, and effects-of-kidney-disease subscales exceeded a Cronbach alpha of 0.80.
- Confirms the international applicability of the KDQOL-36 as the standard ESRD-specific health-related quality-of-life instrument required for CMS quality reporting in U.S. dialysis facilities.
“The Chinese version of the Kidney Disease Quality of Life-36 demonstrates acceptable reliability and validity for use in dialysis patients, supporting its cross-cultural applicability for ESRD-specific quality-of-life assessment.”
- (2022). Health-related quality of life and associated factors among patients on hemodialysis at tertiary care hospitals in Addis Ababa, Ethiopia: a cross-sectional study using the KDQOL-36. BMC Nephrology.
doi:10.1186/s12882-022-02933-1
- Cross-sectional study using the KDQOL-36 among 277 hemodialysis patients across tertiary-care hospitals in Addis Ababa, Ethiopia.
- Health-related quality of life scores in symptom and effects-of-kidney-disease domains were substantially below comparator U.S. and European cohorts, reflecting the additional burden of resource-limited dialysis programs.
- Comorbid depression, longer dialysis vintage, and inadequate dialysis adequacy were independently associated with worse KDQOL-36 scores.
“Health-related quality of life among hemodialysis patients in Addis Ababa was substantially impaired, with depression, dialysis vintage, and adequacy emerging as the strongest modifiable correlates.”
- (2018). Racial differences in completion of the living kidney donor evaluation process. Clinical Transplantation.
doi:10.1111/ctr.13291
- Cohort study of prospective living kidney donor candidates evaluated at a major U.S. transplant center across racial and ethnic groups.
- Black and Hispanic donor candidates completed the multistep evaluation process at lower rates than White candidates after adjusting for medical and demographic covariates.
- Identified intervenable points in the evaluation pipeline where targeted navigation, financial-toxicity support, and culturally competent psychosocial assessment could reduce attrition.
“Racial and ethnic disparities in completion of the living kidney donor evaluation process represent a modifiable contributor to inequities in access to living-donor kidney transplantation.”
- (2017). KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation.
doi:10.1097/TP.0000000000001769
- International KDIGO guideline establishing the global standard for medical, surgical, and psychosocial evaluation of prospective living kidney donors.
- Mandates psychosocial assessment of every living donor candidate to evaluate motivation, decisional capacity, social support, mental health history, and risk for coercion or financial inducement.
- Recommends donor advocate roles, structured documentation of informed consent, and lifetime follow-up of donors for both medical and psychosocial outcomes.
“Psychosocial evaluation is an essential component of living kidney donor candidate assessment, encompassing motivation, decisional capacity, mental health, social support, and the absence of coercion or undue financial pressure.”
- (2024). Application of the Transplant Evaluation Rating Scale in living kidney donor candidates: a contemporary single-center cohort. Transplant International.
doi:10.3389/ti.2024.12521
- Contemporary application of the Transplant Evaluation Rating Scale (TERS) to a single-center cohort of living kidney donor candidates.
- TERS-based psychosocial categorization identified subgroups of donor candidates with elevated risk for postoperative psychological distress and impaired adjustment.
- Reinforces TERS as a complement to SIPAT and PACT in living-donor psychosocial assessment, particularly for centers seeking a longer-form clinical-interview anchored instrument.
“The Transplant Evaluation Rating Scale identified clinically meaningful psychosocial risk strata in a contemporary cohort of living kidney donor candidates, supporting its continued role alongside SIPAT and PACT in pretransplant evaluation.”
- (2018). Comparison of the Safety Planning Intervention with follow-up vs usual care of suicidal patients treated in the emergency department. JAMA Psychiatry.
doi:10.1001/jamapsychiatry.2018.1776
- Cohort comparison study of 1,640 suicidal patients across 9 emergency departments comparing the Safety Planning Intervention plus structured follow-up phone outreach with usual care.
- Intervention arm showed a 45% reduction in suicidal behaviors over 6 months compared with the usual-care comparison group.
- Engagement in outpatient mental-health treatment was approximately twice as high in the intervention arm relative to usual care.
“The Safety Planning Intervention combined with structured telephone follow-up was associated with a substantial reduction in suicidal behavior and increased outpatient treatment engagement among emergency-department patients.”
- (2013). HIPAA Security Rule — Technical Safeguards (45 CFR § 164.312). Code of Federal Regulations, Title 45 — Public Welfare.
Source
- Mandates access control, audit controls, integrity controls, person-or-entity authentication, and transmission security as technical safeguards for ePHI.
- Encryption and decryption are addressable specifications under access control and transmission security — required unless an alternative measure is documented as equally protective.
- Audit controls require hardware, software, and procedural mechanisms to record and examine activity in systems containing or using ePHI.
“A covered entity or business associate must implement technical policies and procedures for electronic information systems that maintain electronic protected health information to allow access only to those persons or software programs that have been granted access rights.”